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Improvements in life expectancy among people living with human immunodeficiency virus (PLWH) receiving
antiretroviral treatment in the United States and Canada might differ among key populations. Given the difference
in substance use among key populations and the current opioid epidemic, drug- and alcohol-related deaths might
be contributing to the disparities in life expectancy. We sought to estimate life expectancy at age 20 years in
key populations (and their comparison groups) in 3 time periods (2004–2007, 2008–2011, and 2012–2015) and
the potential increase in expected life expectancy with a simulated 20% reduction in drug- and alcohol-related
deaths using the novel Lives Saved Simulation model. Among 92,289 PLWH, life expectancy increased in all
key populations and comparison groups from 2004–2007 to 2012–2015. Disparities in survival of approximately a
decade persisted among black versus white men who have sex with men and people with (vs. without) a history of
injection drug use. A 20% reduction in drug- and alcohol-related mortality would have the greatest life-expectancy
benefit for black men who have sex with men, white women, and people with a history of injection drug use.
Our findings suggest that preventing drug- and alcohol-related deaths among PLWH could narrow disparities in
life expectancy among some key populations, but other causes of death must be addressed to further narrow
the disparities.
black women; drug- and alcohol-related deaths; health disparities; Hispanic adults; HIV; life expectancy; men
who have sex with men; people who inject drugs
Abbreviations: AIDS, acquired immune deficiency syndrome; ART, antiretroviral therapy; HIV, human immunodeficiency virus;
IDU, injection drug use; LISSO, Lives Saved Simulation; MSM, men who have sex with men; NA-ACCORD, North American
AIDS Cohort Collaboration on Research and Design; PLWH, people living with human immunodeficiency virus.
With advances over the past several decades in the effi-
cacy and tolerability of antiretroviral therapy (ART), human
immunodeficiency virus infection (HIV)-related morbidity
and mortality have declined markedly and durably (1–3).
Life expectancy, a key indicator encompassing mortality
trends across the life span within a population, has shown
a concomitant dramatic increase among people living with
HIV (PLWH) accessing standard-of-care treatment (4, 5). A
meta-analysis published in 2017 indicated that an additional
43 years of life at age 20 could be expected for PLWH
on ART, a 10-year increase compared with findings from
studies conducted in the late 1990s (6).
After steady increases in life expectancy over the several
preceding decades among the general US population, a 0.1-
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year decrease occurred between 2014 and 2015, and again
between 2015 and 2016 (7, 8). This consecutive-year decline
in life expectancy in the US general population was unprece-
dented and translates into nearly a quarter of a million years
of life lost each year in the United States (9). A major
driver of this decrease is increasing drug- and alcohol-related
deaths, including opioid-related deaths (10–12). PLWHhave
been shown to have higher rates of underlying substance use
disorders (including opioids) and chronic pain (for which
opioids could be prescribed) (13, 14).
Not all PLWH experience equivalent life expectancy;
significant disparities exist among key populations. Previous
estimates of life expectancy published from the North Amer-
ican AIDS Cohort Collaboration on Research and Design
(NA-ACCORD) indicated that life expectancy at age 20 was
51.4 years overall in 2006–2007; life expectancy at age 20
was 48.4 years among nonwhite PLWH compared with 56.9
years among white individuals, 28.8 years among people
who inject drugs, and 69.3 years among men who have sex
with men (MSM) (4). These findings were consistent with
other studies that have shown a 10-year difference in life
expectancy among black compared with white PLWH, a
20-year shorter life expectancy among people who inject
drugs and those with hepatitis C virus coinfection, and
an equivalent or increased life expectancy among MSM
compared with heterosexual PWLH (15–21). It is unknown
whether the increase in drug- and alcohol-related deaths has
affected disparities in life expectancy among key popula-
tions with HIV.
In this study, we estimated observed life expectancy esti-
mates for several key populations of PLWH using mortal-
ity rates from the NA-ACCORD, highlighting disparities
between key populations and their appropriate compari-
son groups. Next, we developed the Lives Saved Simu-
lation (LISSO) model to estimate the potential narrowing
of “expected” life-expectancy disparities that could occur
between key populations and their appropriate comparison
groups from a simulated 20% reduction in the number
of drug- and alcohol-associated deaths among adults with
HIV. A 20% reduction is the goal set forth in the Healing
Communities Studies, which are funded by the National
Institutes of Health’s Helping to End Addiction Long-Term
initiative (22).
METHODS
Study population
The NA-ACCORD is a collaboration of >20 interval
and clinical cohorts collecting longitudinal data from
PLWH (≥18 years old) in Canada and the United States
(http://www.naaccord.org/). This collaboration is the North
American region of the National Institute of Health’s Inter-
national Epidemiology Databases to Evaluate AIDS con-
sortium. Details of the NA-ACCORD collaboration and its
cohorts have been published elsewhere (23). Briefly, partic-
ipants are eligible to be enrolled in the NA-ACCORD from
contributing clinical cohorts if they have ≥2 clinical visits
within 12 months. After enrollment, participants do not have
to be retained in care to be retained in the NA-ACCORD.
Individual-level data are pooled and harmonized and
then undergo quality-control procedures for accuracy and
completeness at the central Data Management Core (Uni-
versity of Washington, Seattle, Washington). The data then
undergo additional quality-control procedures and assembly
into analysis-ready summary files at the Epidemiology/
Biostatistics Core (Johns Hopkins University, Baltimore,
Maryland). The institutional review boards at each partici-
pating cohort and at the Johns Hopkins University School
of Medicine have approved all human subject activities
conducted within the NA-ACCORD.
Cohorts were included in the present study if they pro-
vided cause-of-death information (20 cohorts). Individuals
were included in this analysis if they were prescribed ART
between January 2004 and December 2015.
Deaths and alcohol- and drug-related deaths
Information regarding deaths was obtained through
linkages with vital statistics registries (including the US
National Death Index Plus), physician report, and/or
outreach to the decedent’s survivors. Previously, the NA-
ACCORD reported similar mortality rates among cohorts
that do, and do not, link to death registries (4). Alcohol- and
drug-related deaths were identified in cohorts submitting
National Death Index Plus matching or death certificate
information using International Classification of Diseases
(revisions 9 and 10) codes identified by the National Center
for Health Statistics (K70, X40–X44, X60–X64, X85, and
Y10–Y14) (24). A free-text search in cause-of-death data
was applied to the deaths that were submitted from physician
report and/or outreach to the decedent (see Web Appendix
1, available at https://academic.oup.com/aje).
Demographic characteristics
Age, sex, race/ethnicity, and HIV acquisition risk were
classified at entry into theNA-ACCORD.Agewas estimated
from year of birth. Sex was classified as male or female;
there was an insufficient sample size to estimate observed
mortality rates by age group and calendar period among
transgender and intersex individuals. Race was identified as
black or white, regardless of Hispanic ethnicity. Hispanic
ethnicity (yes/no) and HIV acquisition risk (MSM and
having a history of injection drug use (IDU)) were collected.
These characteristics were used to identify the following
key populations of interest: black (vs. white) MSM,
black (vs. white) women, Hispanic (vs. non-Hispanic)
adults, and people with a history of IDU (vs. those
without).
CD4 count and a history of an acquired immune defi-
ciency syndrome (AIDS)-defining illness were measured
to describe the population and to allow for comparison of
our estimates with previous estimates of life expectancy
in PLWH (3). CD4 count was measured as close to study
entry as possible, within the window of before to 3 months
after study entry. A clinical AIDS diagnosis at, or prior to,
study entry was defined as diagnosis with an AIDS-defining
opportunistic infection or cancer.
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Statistical analysis: observed mortality rates and life
expectancy, and simulated mortality rates and life
expectancy using the LISSO model
Participants contributed deaths and person-years from
age 20 years or January 1, 2004, (whichever came last) to
the date of death, loss to follow-up (defined as a gap of
>2 years without a CD4 or HIV RNA measurement), or
administrative censoring at either the date through which the
cohort ascertained cause of death information or December
31, 2015 (whichever came first).
Observed mortality rates per 1,000 person-years were
calculated as the number of observed deaths divided by the
number of observed person-years× 1,000. Observedmortal-
ity rates were estimated in 5-year age groups (20–24, 25–29,
30–34, 35–39, 40–44, 45–49, 50–54, 55–59, 60–64, 65–69,
70–74, 75–79, ≥80) for each calendar period (2004–2007,
2008–2011, and 2012–2015) within each key population and
comparison group. Then mortality rates were standardized
to the 2000 US Standard Population (25) to account for the
increasing mean age in the age groups between calendar
periods. In some of the key populations and comparison
groups, mortality rates were unstable, particularly at older
ages, due to smaller amounts of person-time and deaths
observed. Age groups were then collapsed to 10-year age
groups (20–29, 30–39, 40–49, 50–59, 60–69, 70–79, ≥80)
to increase the stability of the mortality rates.
Observed life expectancy was estimated using single-
decrement, abridged period life tables (a standard approach)
constructed from the observed mortality rates estimated
for each decade of age in each calendar period for each
key population and comparison group; the Chiang method
was used to calculate the 95% confidence intervals (26).
Life expectancy estimates can be interpreted as the average
additional number of years that a 20-year-old with treated
HIVwill live, assuming constant age-specific mortality rates
across that individual’s lifetime.
Anticipated (i.e. “expected”) life expectancy gained from
a specified decrease in drug- and alcohol-related deaths was
estimated by adapting the approach developed by Case and
Deaton, which estimates the number of “lives saved” for
each calendar year and age stratum after a reduction in
a cause-specific mortality rate (11). In this approach, the
population saved experiences themortality rate of their peers
as well as the opportunity for a proportion of the population
to age into older age categories. For more details of the
approach, please see Web Appendix 2 and the supplemental
information to Case and Deaton’s paper (27). The Case
and Deaton approach uses aggregated population counts and
mortality rates in calendar time and age strata.
We built the LISSO agent-based simulation model using
individual-level data from the NA-ACCORD, including the
age at death for those who are saved. We randomly selected
20% of the individuals (i.e., agents) in each key population
and comparison group who were observed to die from drug-
and alcohol-related causes to be “saved” and subsequently
experience the same overall mortality risk as their peers (i.e.,
the probability of death within the calendar period and age
stratum) and/or the opportunity to age into the older age
groups (Figure 1). The random selection of the 20% saved
Figure 1. A schematic of the Lives Saved Simulation model, an
agent-based simulation model that randomly selects 20% of those
who died to be “saved” and experience the subsequent mortality risk
of their peers, as well as the opportunity to age into older age groups.
was simulated 100 times, and mortality rates were estimated
for each simulation; the median mortality rates were used to
estimate the expected life expectancy at age 20 in each calen-
dar year period within each key population and comparison
group. These life expectancy estimates can be interpreted as
the average additional number of years that a 20-year-old
with treated HIV would live if there was a 20% decrease
in drug- and alcohol-related deaths, assuming constant age-
specific mortality rates across that individual’s lifetime.
The observed mortality rates, the LISSO model, and the
expected mortality rates were estimated using SAS (SAS
Institute, Inc., Cary, North Carolina). The single-decrement,
abridged period life table approach to life expectancy was
estimated using Microsoft Excel (Microsoft Corp., Red-
mond, Washington).
RESULTS
Among 132,664 participants in 20 cohorts with cause-
of-death data available, 92,289 were prescribed ART and
under observation in our study, of whom 13,349 (14%)
died; median follow-up was 5.4 (interquartile range, 2.6–
10.0) years. Most participants were male (86%), 42% were
white, 35% were black, 12% were Hispanic, 34% were
Am J Epidemiol. 2019;188(12):2097–2109
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aged ≥50 years, and 19% had IDU for their HIV acquisition
risk. Although 20% of adults had an AIDS-defining illness,
29% of adults had a CD4 count ≥500 cells/mm3 at study
entry. CD4 count at study entry increased most dramatically
from 2008–2011 to 2012–2015 in all key populations and
comparison groups, which is reflective of the 2012 “treat
all” guidelines change that recommended all receive prompt
treatment, regardless of CD4 count. Characteristics stratified
by key population and comparison group can be found in
Table 1.
Overall mortality rates decreased over time in all key pop-
ulations and comparison groups. Correspondingly, observed
life expectancy increased from 2004–2007 to 2012–2015 in
both the key populations and comparison groups (Figure 2,
Web Table 1). Observed life expectancy among white
MSM in 2012–2015 (60.3 years at age 20) exceeded life
expectancy of white men in the general US population (57.1
years at age 20 in 2015); however, observed life expectancy
estimates for other key populations and comparison groups
of PLWH were less than life expectancy in the general US
population (8).
Disparities in observed life expectancy at age 20 narrowed
for black versus white MSM from 2004–2007 (33.0 vs.
52.3 years, respectively) to 2012–2015 (50.9 vs. 60.3 years,
respectively), and for IDU versus non-IDU history (26.5 in
2004–2007 and 39.9 in 2012–2015 vs. 37.1 in 2004–2007
and 50.3 in 2012–15, respectively, Figure 2, Web Table 1).
Reflective of the general population, Hispanic adults with
HIV had greater observed life expectancy than non-Hispanic
adults with HIV, and the disparity grew (for 2004–2007, 35.9
vs. 34.9 years; for 2012–2015, 51.2 vs. 47.8 years, respec-
tively) (28). Among black versus white women, observed
life expectancy was higher among white women in 2004–
2007 (33.1 vs. 39.7 years) and 2008–2011 (40.8 vs. 43.4
years), but blackwomen had longer observed life expectancy
in 2012–2015 (55.7 vs. 49.5 years).
The proportion of alcohol- and drug-related deaths was
higher in all comparison groups than in key populations,
except for those with IDU versus non-IDU risk; only
being a white woman in 2008–2011 and 2012–2015 and
having a history of IDU in 2012–2015 were associated
with >20% drug- and alcohol-related deaths (Figure 3).
Although the proportion of drug- and alcohol-related deaths
increased among white women over time, the proportion
of white women who had IDU risk was constant over
time (52% in 2004–2007, 53% in 2008–2011, and 54% in
2012–2015).
After applying the LISSO model to reducing the number
drug- and alcohol-related deaths by 20%, increases in life
expectancy of ≥1 year were seen among black MSM (in
2012–2015), white women (in 2004–2007), and those with
a history of IDU (in 2012–2015, Table 2). The observed and
expected life-expectancy estimates were higher in the black
(vs. white) women and Hispanic (vs. non-Hispanic) adults
in 2012–2015. Although reducing the number of drug- and
alcohol-related deaths by 20% had differential impact on the
expected life expectancy among key populations and com-
parison groups, the percentage change in the life-expectancy
disparity showed a narrowing for black (vs. white)MSM and
those with a history of IDU (vs. non-IDU) in 2012–2015.
DISCUSSION
There was an increase in observed life expectancy in all
key populations and comparison groups using ART from
2004–2007 to 2012–2015; however, disparities persisted in
both observed life expectancies and expected life expectan-
cies after simulating a 20% reduction in drug- and alcohol-
related deaths. Disparities in observed life expectancy nar-
rowed over time for black (vs. white MSM) and those with
a history of IDU (vs. non-IDU). Observed life expectancy
was lower among black (vs. white) women in 2004–2007
and 2008–2011, but it was greater among black versus white
women in 2012–2015. After simulating a 20% reduction in
drug- and alcohol-related deaths, expected life expectancy
increased differentially in key populations and over time,
with black MSM (in 2012–2015), white women (in 2004–
2007), and those with IDU history (in 2012–2015) hav-
ing the greatest increase in expected life expectancy. The
observed and expected life-expectancy disparities and the
percent change in life-expectancy disparity narrowed in all
key populations (vs. comparison groups) in the most recent
period (2012–2015), except for black (vs. white) women.
Nevertheless, our results suggest that observed disparities in
life expectancy among key populations persist, and that the
specified 20% reduction in drug- and alcohol-related deaths
among adults with HIV might slightly narrow disparities in
some of the key populations of PLWH.
Our findings update observed life-expectancy estimates
among PLWH and add nuance by demonstrating persistent
disparities in observed life expectancy in key populations
of PLWH. Although prior studies have reported trends in
observed life expectancy among PLWH in the United States
and Canada according to sex, race, ethnicity, HIV acquisi-
tion risk, and CD4 count (4, 15–18), our study examines dis-
parities in observed life expectancy in key populations ver-
sus their comparison groups among PLWH. Compared with
sex- and race-stratified observed life-expectancy estimates
in similar years in the general population, our observed life
expectancy at age 20 years among PLWH was lower in all
key populations and comparison groups, with the exception
of white MSM from 2012–2015, who had an observed life
expectancy 3.2 years greater than white men at age 20 in the
general population in 2015 (8). This difference could be due
to an increased frequency of health-care encounters among
whiteMSMwithHIV and on treatment comparedwithwhite
men in the general population. It is notable that the observed
life-expectancy disparity in black versus white MSM with
HIV narrowed but persisted, with the greatest decrease in
disparity from 2004–2007 to 2008–2011, followed by a
slight widening of the disparity from 2008–2011 to 2012–
2015, resulting in an observed life expectancy gap of 9.4
years in black versus white MSM. This pattern was also
present for IDU versus non-IDU history with HIV, resulting
in an observed gap of 10.4 years in the most recent time
period. In the context of HIV, where guidelines changed
in 2012 to “treat everyone,” persistent racial disparities
among MSM and disparities among IDU histories suggest
the potential roles of structural racism and stigma, which can
reduce access to and retention in health care and result in
disparities in observed life expectancy (29–31).
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Figure 2. Observed increases in life expectancy (LE) at age 20 years among people with human immunodeficiency virus (left column, panels
A, C, E, and G), and corresponding changes in disparities in key populations and their comparison groups (right column, panels B, D, F, and
H) in the North American AIDS Cohort Collaboration on Research and Design, United States and Canada, 2004–2015. IDU, injection drug use;
MSM, men who have sex with men.
Our finding of a greater observed life expectancy in black
(vs. white) women in 2012–2015 was unexpected; this was
a reversal of the difference in observed life expectancy
prior to the most recent time period. Black women had the
greatest increase in observed life expectancy in any group
from one period to the next (14.9 years) from 2008–2011
to 2012–2015, as well as an 18-percentage-point increase
in the proportion with a CD4 count ≥500 cells/mm3 at
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Figure 3. Observed (solid lines) life expectancy from the North American AIDS Cohort Collaboration on Research and Design (United States
and Canada, 2004–2015) and expected (dashed lines) life expectancy from the Lives Saved Simulation model, after a 20% reduction in drug-
and alcohol-related deaths, as well as the proportion of drug- and alcohol-related deaths (bars) among key populations and their comparison
groups, including black (purple) compared with white (gray) men who have sex with men (A), black (orange) compared with white (gray) women
(B), Hispanic (teal) compared with non-Hispanic (gray) adults (C), and people who have a history of injection drug use (yellow) compared with
those who do not (gray) (D). Expected life expectancy after a 20% reduction in drug- and alcohol-related deaths was estimated as the median
estimate from 100 simulations using the Lives Saved Simulation model.
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study entry. These increases might be attributed in part to
timelier HIV testing, linkage to care, and treatment initiation
efforts focused on women of color. Conversely, observed
life expectancy among white women increased modestly,
by 6.1 years, to 49.5 years at age 20 from 2008–2011 to
2012–2015. White women had nearly double the proportion
of drug- and alcohol-related deaths as black women in
2008–2011 and 2012–2015, suggesting differential influ-
ence of the opioid epidemic on white and black women with
HIV.
The application of the LISSO model is intended for
public health planning; it estimates the corresponding
increase in life expectancy from a specified decrease in
drug- and alcohol-related mortality. Approximately 63%
of 52,404 overdose deaths were attributed to opioids in
2015 in the United States (12). The number of overdose
deaths continued to increase beyond the end of our study
period (2015) until a plateau in 2018; thus, the impact of
a 20% reduction in drug- and alcohol-deaths might result
in greater increases in life expectancy after 2015 (32).
There are numerous evidence-informed strategies to reduce
opioid deaths, including broadening naloxone availability,
expanding methadone-assisted treatment, monitoring opioid
prescription information, and intensifying the punishments
for the illicit supplying of opioids (33–36). However,
preventing nonopioid drug- and alcohol-related deaths
as well as other major causes of death (particularly the
causes of death among younger adults, because those deaths
are more influential on the life-expectancy estimate than
deaths at older ages) for key PLWH populations must not
be overlooked in order to further reduce disparities. The
effectiveness of interventions to reduce drug- and alcohol-
related deaths (ideally estimated from study populations
of the key populations and comparison groups) must be
incorporated by program decision-makers.
Our agent-based simulation model is a novel adaptation
of the Case and Deaton “lives saved” approach—it allows
application of the approach to individuals by randomly
saving 20% of those who died from drug- and alcohol-
related causes and then applying subsequentmortality risk of
their peers and the opportunity to age into older age groups
to those saved. Creating new conditional probabilities of
dying in each age interval after being “saved” employs
the same assumptions as hazard independence (indepen-
dence from competing causes of death) and force of mor-
tality (uniform distribution of deaths across an age interval)
as a cause-deleted life table, which is a more traditional
approach.
Limitations include cause-specific mortality as deter-
mined by death certificate information and matching to
the National Death Index Plus, which has unavoidable
misclassification: There might be an underascertainment of
drug- and alcohol-related deaths. Second, there are sequelae
to long-term moderate to severe use of drugs and alcohol
(37, 38). Preventing mortality from these causes is not
a solution in and of itself; addressing significant health
consequences related to substance use, such as liver disease,
will be important. Third, we did not account for hepatitis C
virus infection and its newer treatments (the first of which
was approved in October of 2014), which could affect life
expectancy, particularly among those with a history of IDU.
Fourth, we were unable to account for socioeconomic-
status differences between our key populations and their
comparison groups; certainly, these differences affect life
expectancy, but they probably do not wholly account for
the racial and HIV acquisition risk–based disparities in
our key populations and comparison groups. Fifth, the
interpretation of life expectancy relies upon constant age-
specific mortality trends across the life span. By restricting
to the calendar period of January 2004 to December 2015,
we eliminated the impact of the dramatically declining
mortality rates that immediately followed the advent of
effective HIV treatment and diminishing thresholds to
initiate treatment that occurred prior to 2004. Sixth, our
findings are most applicable to the target population of
PLWH in the United States who have successfully linked
into care and initiated ART (target population); the NA-
ACCORD is the largest (albeit nonrandom) sample of
this population with demographic characteristics similar
to that of the Medical Monitoring Project (which was
sampled to be representative of persons in HIV care in
the United States; details of this comparison available at
http://www.naaccord.org/). Finally, as life expectancy
among PLWH continues to increase (even in the setting of
persistent disparities), efforts must focus on improving not
only the duration but also the quality of life among PLWH.
Interventions to improve the quality of life among PLWH
through prevention, screening, and treatment of non-HIV
related comorbidities are essential to successful aging with
HIV (39).
Life expectancy among PLWH continues to increase, with
the good news of narrowing disparities in black and white
MSM, and substantial increase in life expectancy among
black women. However, life-expectancy disparities persist
among black versus white MSM and persons with a history
of IDU (vs. no IDU history), and gains in life expectancy
over time among white women (for whom 20% of deaths
were drug- and alcohol-related) did not keep pace with
the other groups. The increases in expected life expectancy
with a simulated 20% decrease in drug- and alcohol-related
deaths narrowed life-expectancy disparities for most groups,
however other causes of death must be addressed to further
narrow life-expectancy disparities.
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